市場調查報告書

全球抗病毒治療市場:按類型,用途和作用方式進行的機會分析和行業預測(2019-2026)

Anti-Viral Therapies Market by Type, Application, and Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 948560
出版日期 內容資訊 英文 238 Pages
商品交期: 2-3個工作天內
價格
全球抗病毒治療市場:按類型,用途和作用方式進行的機會分析和行業預測(2019-2026) Anti-Viral Therapies Market by Type, Application, and Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2020年05月01日內容資訊: 英文 238 Pages
簡介

2018年,全球抗病毒治療市場規模達到383.16億美元。預計到2019年至2026年,該市場將以2.4%的複合年增長率增長,到2026年將達到462.13億美元。這個市場的主要增長因素是病毒感染的發生率增加,這得益於研發活動的增加以及新產品的開發,例如管道產品之外的疫苗和聯合療法的開發。預計是。此外,在預測期內,亞太地區和拉丁美洲/中東/非洲新興經濟體的組合療法以及開發和批准有望為市場增長提供許多機會。但是,高昂的治療費用以及對替代藥物(例如自然療法藥物和順勢療法)的需求不斷增加,可能會限制該市場的增長。

本報告調查了全球抗病毒治療市場,包括市場機會和影響,增長和限制,按用途進行的市場分析,類型,作用機制和區域,競爭格局,主要公司的概況等。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資產品
    • 成功策略
  • 市場動態
    • 生長因子
      • 病毒感染導致支出激增
      • 更強大的抗病毒藥物渠道
    • 抑制因子
      • 治療費用高
    • 市場機會
      • 用於聯合療法的產品批准數量增加

第4章市場分析:按用途

  • 概述
    • 市場規模和預測
  • 艾滋病毒
  • 肝炎
  • 皰疹病毒
  • 流感
  • 其他

第5章市場分析:按類型

  • 概述
    • 市場規模和預測
  • 仿製藥
  • 品牌藥

第6章市場分析:按作用機理

  • 概述
    • 市場規模和預測
  • 核甘酸聚合□抑製劑
  • 逆轉錄□抑製劑
  • 蛋白□抑□□製劑
  • 其他

第7章按地區進行市場分析

  • 概述
    • 市場規模和預測
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東/非洲

第8章公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GILEAD SCIENCES, INC.
  • GlaxoSmithKline Plc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
目錄
Product Code: A06278

Title:
Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global anti-viral therapies market was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral drugs belong to the class of medicines, which are used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines. In addition, most of these drugs are used for specific viral infections, while a few (broad-spectrum antiviral drugs) are effective against a wide range of viruses.

The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.

An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Application

  • HIV
  • Hepatitis
  • Herpes Virus
  • Influenza
  • Other Applications

By Type

  • Generic Drugs
  • Branded Drugs

By Mechanism of Action

  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott Laboratories
  • AstraZeneca plc
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Johnson & Johnson
  • Merck & Co., Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Surge in global burden of viral infection
      • 3.3.1.2.Stronger pipeline of anti-viral drugs
    • 3.3.2.Restraints
      • 3.3.2.1.Higher cost of treatment
    • 3.3.3.Opportunities
      • 3.3.3.1.Increase in number of product approvals for combination therapy

CHAPTER 4:ANTI-VIRAL THERAPIES MARKET, BY APPLICATION

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.HIV
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Hepatitis
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Herpes virus
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Influenza
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Other Applications
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country

CHAPTER 5:ANTI-VIRAL THERAPIES MARKET, BY TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Generic drugs
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Branded drugs
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Nucleotide polymerase inhibitor
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Reverse transcriptase inhibitors
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Protease inhibitors
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country
  • 6.5.Others
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis, by country

CHAPTER 7:GLOBAL ANTI-VIRAL THERAPIES MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast, by type
    • 7.2.3.Market size and forecast, by mechanism of action
    • 7.2.4.Market size and forecast, by application
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S. market size and forecast, by type
      • 7.2.5.2.U.S. Market size and forecast, by mechanism of action
      • 7.2.5.3.U.S. market size and forecast, by application
      • 7.2.5.4.Canada market size and forecast, by type
      • 7.2.5.5.Canada Market size and forecast, by mechanism of action
      • 7.2.5.6.Canada market size and forecast, by application
      • 7.2.5.7.Mexico market size and forecast, by type
      • 7.2.5.8.Mexico Market size and forecast, by mechanism of action
      • 7.2.5.9.Mexico market size and forecast, by application
  • 7.3.Europe
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Market size and forecast, by type
    • 7.3.3.Market size and forecast, by mechanism of action
    • 7.3.4.Market size and forecast, by application
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany market size and forecast, by type
      • 7.3.5.2.Germany Market size and forecast, by mechanism of action
      • 7.3.5.3.Germany market size and forecast, by application
      • 7.3.5.4.France market size and forecast, by type
      • 7.3.5.5.France Market size and forecast, by mechanism of action
      • 7.3.5.6.France market size and forecast, by application
      • 7.3.5.7.UK market size and forecast, by type
      • 7.3.5.8.UK Market size and forecast, by mechanism of action
      • 7.3.5.9.UK market size and forecast, by application
      • 7.3.5.10.Italy market size and forecast, by type
      • 7.3.5.11.Italy Market size and forecast, by mechanism of action
      • 7.3.5.12.Italy market size and forecast, by application
      • 7.3.5.13.Spain market size and forecast, by type
      • 7.3.5.14.Spain Market size and forecast, by mechanism of action
      • 7.3.5.15.Spain market size and forecast, by application
      • 7.3.5.16.Rest of Europe market size and forecast, by type
      • 7.3.5.17.Rest of Europe Market size and forecast, by mechanism of action
      • 7.3.5.18.Rest of Europe market size and forecast, by application
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Market size and forecast, by type
    • 7.4.3.Market size and forecast, by mechanism of action
    • 7.4.4.Market size and forecast, by application
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan market size and forecast, by type
      • 7.4.5.2.Japan Market size and forecast, by mechanism of action
      • 7.4.5.3.Japan market size and forecast, by application
      • 7.4.5.4.China market size and forecast, by type
      • 7.4.5.5.China Market size and forecast, by mechanism of action
      • 7.4.5.6.China market size and forecast, by application
      • 7.4.5.7.India market size and forecast, by type
      • 7.4.5.8.India Market size and forecast, by mechanism of action
      • 7.4.5.9.India market size and forecast, by application
      • 7.4.5.10.Australia market size and forecast, by type
      • 7.4.5.11.Australia Market size and forecast, by mechanism of action
      • 7.4.5.12.Australia market size and forecast, by application
      • 7.4.5.13.South Korea market size and forecast, by type
      • 7.4.5.14.South Korea Market size and forecast, by mechanism of action
      • 7.4.5.15.South Korea market size and forecast, by application
      • 7.4.5.16.Rest of Asia-Pacific market size and forecast, by type
      • 7.4.5.17.Rest of Asia-Pacific Market size and forecast, by mechanism of action
      • 7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.Market size and forecast, by type
    • 7.5.3.Market size and forecast, by mechanism of action
    • 7.5.4.Market size and forecast, by application
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil market size and forecast, by type
      • 7.5.5.2.Brazil Market size and forecast, by mechanism of action
      • 7.5.5.3.Brazil market size and forecast, by application
      • 7.5.5.4.Saudi market size and forecast, by type
      • 7.5.5.5.Saudi Market size and forecast, by mechanism of action
      • 7.5.5.6.Saudi market size and forecast, by application
      • 7.5.5.7.South Africa market size and forecast, by type
      • 7.5.5.8.South Africa Market size and forecast, by mechanism of action
      • 7.5.5.9.South Africa market size and forecast, by application
      • 7.5.5.10.Rest of LAMEA market size and forecast, by type
      • 7.5.5.11.Rest of LAMEA Market size and forecast, by mechanism of action
      • 7.5.5.12.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.AbbVie Inc.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Business performance
    • 8.2.5.Key strategic moves and developments
  • 8.3.Bristol Myers Squibb Company
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.F. Hoffmann-La Roche Ltd.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Johnson & Johnson
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Business performance
  • 8.6.Merck & Co., Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Business performance
    • 8.6.5.Key strategic moves and developments
  • 8.7.GILEAD SCIENCES, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.GlaxoSmithKline Plc.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.AstraZeneca PLC
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.Aurobindo Pharma Limited
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 02.HIV ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 03.HEPATITIS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 04.HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 05.INFLUENZA ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 06.OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 07.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 08.ANTI-VIRAL THERAPIES MARKET FOR GENERIC DRUGS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 09.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 10.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION, 2018-2026 ($MILLION)
  • TABLE 11.ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR, BY REGION, 2018-2026 ($MILLION)
  • TABLE 12.ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13.ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 14.ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 15.GLOBAL ANTI-VIRAL THERAPIES MARKET BY REGION, 2018-2026, ($MILLION)
  • TABLE 16.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 17.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 18.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 19.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 20.U.S. ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 21.U.S. ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 22.U.S. ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 23.CANADA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 24.CANADA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 25.CANADA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 26.MEXICO ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 27.MEXICO ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 28.MEXICO ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 29.EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 30.EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 31.EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 32.EUROPE ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 33.GERMANY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 34.GERMANY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 35.GERMANY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 36.FRANCE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 37.FRANCE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 38.FRANCE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 39.UK ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 40.UK ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 41.UK ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 42.ITALY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 43.ITALY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 44.ITALY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 45.SPAIN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 46.SPAIN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 47.SPAIN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 48.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 49.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 50.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 51.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 52.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 53.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 54.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 55.JAPAN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 56.JAPAN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 57.JAPAN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 58.CHINA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 59.CHINA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 60.CHINA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 61.INDIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 62.INDIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 63.INDIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 64.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 65.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 66.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 67.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 68.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 69.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 70.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 73.LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 74.LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 75.LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 76.LAMEA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 77.BRAZIL ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 78.BRAZIL ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 79.BRAZIL ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 80.SAUDI ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 81.SAUDI ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 82.SAUDI ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 83.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 84.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 85.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 86.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 87.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 88.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 89.ABBOTT: COMPANY SNAPSHOT
  • TABLE 90.ABBOTT: OPERATING SEGMENTS
  • TABLE 91.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 92.ABBVIE: COMPANY SNAPSHOT
  • TABLE 93.ABBVIE: OPERATING SEGMENTS
  • TABLE 94.BMS: COMPANY SNAPSHOT
  • TABLE 95.BMS: OPERATING SEGMENTS
  • TABLE 96.BMS: PRODUCT PORTFOLIO
  • TABLE 97.ROCHE: COMPANY SNAPSHOT
  • TABLE 98.ROCHE: OPERATING SEGMENTS
  • TABLE 99.ROCHE: PRODUCT PORTFOLIO
  • TABLE 100.J&J: COMPANY SNAPSHOT
  • TABLE 101.J&J: OPERATING SEGMENTS
  • TABLE 102.MERCK: COMPANY SNAPSHOT
  • TABLE 103.MERCK: OPERATING SEGMENTS
  • TABLE 104.GILEAD: COMPANY SNAPSHOT
  • TABLE 105.GILEAD: OPERATING SEGMENTS
  • TABLE 106.GILEAD: PRODUCT PORTFOLIO
  • TABLE 107.GSK.: COMPANY SNAPSHOT
  • TABLE 108.GSK: OPERATING SEGMENTS
  • TABLE 109.GSK: PRODUCT PORTFOLIO
  • TABLE 110.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 111.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 112.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 113.AUROBINDO: COMPANY SNAPSHOT
  • TABLE 114.AUROBINDO: OPERATING SEGMENTS
  • TABLE 115.AUROBINDO: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ANTI-VIRAL THERAPIES MARKET SEGMENTATION
  • FIGURE 01.TOP INVESTMENT POCKETS
  • FIGURE 02.TOP WINNING STRATEGIES, BY YEAR, 2016-2019*
  • FIGURE 03.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2019* (%)
  • FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2016-2019*
  • FIGURE 05.TOP IMPACTING FACTORS
  • FIGURE 06.COMPARATIVE ANALYSIS OF HIV ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 07.COMPARATIVE ANALYSIS OF HEPATITIS ANTI VIRAL THERAPIES MARKE BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 08.COMPARATIVE ANALYSIS OF HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 09.COMPARATIVE ANALYSIS OF INFLUENZA ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 10.COMPARATIVE ANALYSIS OF OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11.ANTI-VIRAL THERAPIES FOR GENERIC DRUGS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 13.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 17.ABBOTT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 18.ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 19.ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 20.ABBVIE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 21.ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 22.ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 23.BMS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 24.BMS: REVENUE SHARE BY SEGMENT, 2018(%)
  • FIGURE 25.BMS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 26.ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 28.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 29.J&J: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 30.J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 31.J&J: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 32.MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33.MERCK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 34.GILEAD: REVENUE, 2016-2018($MILLION)
  • FIGURE 35.GILEAD: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 36.GSK: REVENUE, 2016-2018($MILLION)
  • FIGURE 37.GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 38.GSK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 39.ASTRAZENECA: NET SALES, 2016-2018 ($THOUSAND)
  • FIGURE 40.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 41.ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 42.AUROBINDO: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 43.AUROBINDO: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 44.AUROBINDO: REVENUE SHARE BY REGION, 2018 (%)